Curative Biotechnology Advances Translational Ophthalmology Program Through PennVet Research Agreement

PennVet Study to Evaluate GMP-Grade Metformin Eye Drops in a Canine Model Supporting Human and Veterinary Development Pathways Palm Beach Gardens, FL, May 07, 2026 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) ("Curative" or the "Company"), a development-stage biomedical company focused on novel therapies for degenerative eye diseases, today announced that it has entered into a Sponsored Research Agreement with the University of Pennsylvania's School of Veterinary Medicine ("PennVet") to support a K9 study evaluating its metformin-based topical ophthalmic formulation (eye drops).